Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis

Joint Bone Spine

Volumn 80, Issue 6, 2013, Pages 608-612

  Osiri, Manathip ^a   Sattayasomboon, Youwanuch ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Comorbid condition; Direct medical costs; Disease modifying antirheumatic drugs; Rheumatoid arthritis; Societal perspective

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; CALCIUM; CHLOROQUINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; VITAMIN D;

ADULT; AGE; ALLERGIC RHINITIS; ARTICLE; CATARACT; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DYSLIPIDEMIA; ENDOMETRIUM POLYP; FEMALE; GLAUCOMA; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KERATOCONJUNCTIVITIS SICCA; MAJOR CLINICAL STUDY; MALE; NONARTICULAR RHEUMATISM; OSTEOARTHRITIS; OSTEOPOROSIS; OTITIS MEDIA; OUTPATIENT CARE; RHEUMATOID ARTHRITIS; SINUSITIS; SKIN DISEASE; UTERUS MYOMA; AGED; AMBULATORY CARE; ARTHRITIS, RHEUMATOID; ECONOMICS; MIDDLE AGED; PREVALENCE; THAILAND;

ADULT; AGED; AMBULATORY CARE; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; THAILAND;

EID: 84888440734     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.01.013     Document Type: Article

References (20)

1. Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11:229.
2. Osiri M., Maetzel A. The economic burden of rheumatoid arthritis: Asia/Thailand perspective. Handbook of disease burdens and quality of life measures 2010, 1733-1750. Springer Science+Business Media, New York. V.R. Preedy, R.R. Watson (Eds.).
3. Kvien T.K. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004, 22:1-12.
4. Wolfe F. The burden of rheumatoid arthritis. Am J Manag Care 1999, 5:S852-S859.
5. Lundkvist J., Kastäng F., Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008, 8:S49-S60.
6. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994, 37:481-494.
7. Symmons D.P., Jones M.A., Scott D.L., et al. Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998, 25:1072-1077.
8. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:885-906.
9. Furst D.E., Chang H., Greenberg J.D., et al. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clin Exp Rheumatol 2009, 27:560-566.
10. Wolfe F., Michaud K., Li T., et al. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010, 37:305-315.
11. Berkanovic E., Hurwicz M.L. Rheumatoid arthritis and comorbidity. J Rheumatol 1990, 17:888-892.
12. Joyce A.T., Smith P., Khandker R., et al. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol 2009, 36:743-752.
13. Kapetanovic M.C., Lindqvist E., Simonsson M., et al. Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20years: lack of association between inflammation and cardiovascular disease. Scand J Rheumatol 2010, 39:353-359.
14. Briggs A.M., March L., Lassere M., et al. Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian Rheumatology Association database. Int J Rheumatol 2009, 2009:861481.
15. Rupp I., Boshuizen H.C., Jacobi C.E., et al. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol 2004, 31:58-65.
16. Heston A, Summers R, Aten B. Penn World Table Version 7.0. Center for International Comparisons of Production, Income and Prices at the University of Pennsylvania, May 2011.
17. Thai Rheumatism Association Working Group Guideline for anti-TNF-α therapies in rheumatoid arthritis. In: Guideline for anti-tumor necrosis factor-α therapies in rheumatic diseases 2006, Thai Rheumatism Association, Bangkok, p.14-9 (in Thai language).
18. Wolfe F., Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61:1563-1570.
19. Osiri M., Maetzel A., Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. J Rheumatol 2007, 34:57-63.
20. Maravic M., Baudens G., Sanchez J.P., et al. rheumatoid arthritis: a medico-economic evaluation from 2008 French Hospital Database. Joint Bone Spine 2012, 79:96-97.